Published
6 months agoon
By
adminShares of CG Oncology could soar from here, according to Guggenheim. The investment firm initiated coverage of the biopharma stock with a buy rating and $90 price target, which implies that shares could surge 137% from their Tuesday close of $38. CG Oncology focuses on developing treatments for bladder cancer. The stock has popped 33% in 2025, outpacing the S & P 500’s 14% in that time. Guggenheim analyst Brad Canino pointed to the company’s solid position within the non-muscle invasive bladder cancer industry. He also applauded CG Oncology’s development of cretostimogene, an oncolytic immunotherapy. “The nascent NMIBC drug market has lots of patients, industry pricing power, and long treatment durations, which makes the CGON story rise to the top of quality oncology ideas, in our view, given the best-in-class efficacy, durability and safety of cretostimogene, which will enter FDA review next year,” he wrote. Canino continued: “These NMIBC patients undergo therapies to prevent invasive operations or bladder removal (cystectomy), which creates motivation to use the most durable product, such as cretostimogene. These patients also have a non-lethal form of cancer and demand a pristine drug safety profile, which we believe cretostimogene provides.” The analyst added that CG Oncology offers a “potentially attractive catalyst path.” This includes numerous data and regulatory updates across multiple segments into the next two years. Analysts are bullish on the stock, with all 12 of the ones covering it assigning a buy or strong buy rating, LSEG data shows. ( Learn the best 2026 strategies from inside the NYSE with Josh Brown and others at CNBC PRO Live. Tickets and info here . )
This industrial giant is emerging as a big AI play, says Wells Fargo
Novo Nordisk’s strategy tested as investors push back on board revamp
Alibaba plans AI subscriptions, stablecoin-like payments with JPMorgan
UK borrowing costs spike on report government to scrap plans to raise income tax
Trump’s threatened the BBC with a $1B lawsuit: Here’s what’s going on
UBS’s picks for global returns next year
Wells Fargo sees Caterpillar continuing to roar higher, emerging as an artificial intelligence play. The bank initiated shares of...
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic...
Key Points Alibaba plans to use “tokenization” of payments for cross-border transactions in its business-to-business arm. Kuo Zhang, president...
Rachel Reeves, U.K. chancellor of the exchequer, delivers a speech in London, UK, on Tuesday, Nov. 4, 2025. Bloomberg...
US President Donald Trump speaks to reporters as he arrives at Palm Beach International Airport on Oct. 31,...
Investors looking for global diversification opportunities should look to a specific subset of stocks in Europe, according to UBS...
Eakarat Buanoi | Istock | Getty Images LISBON, Portugal — Top tech executives told CNBC they’re concerned about...
Tan Su Shan, deputy chief executive officer and managing director of institutional banking at DBS Group Holdings Ltd., speaks during...
CHENGDU, CHINA – OCTOBER 18: People walk past the Louis Vuitton store at Taikoo Li, a high-end shopping area that...
The United States said Thursday it will remove tariffs on some foods and other imports from Argentina, Ecuador, Guatemala and...
